Acamprosate — Membership Pricing

Other medications in Mental Health

• Alprazolam
• Amphetamine Salts
• Aripiprazole
• Asenapine
• Atomoxetine
• Brexanolone
• Brexpiprazole
• Bupropion

About Acamprosate

Acamprosate is a crucial medication prescribed to help individuals maintain abstinence from alcohol, supporting long-term recovery from alcohol dependence. Understanding how it works and its typical costs is vital for those on this journey. With TheDrugClub, members can often discover significant savings on essential prescriptions like acamprosate, making vital treatment more accessible and affordable.

Alcohol dependence is a complex condition that requires comprehensive support, and for many, medication plays a vital role. Acamprosate is one such medication, specifically designed to help individuals who have stopped drinking alcohol to remain alcohol-free.

What Acamprosate Treats

Acamprosate is approved for the maintenance of abstinence in patients with alcohol dependence. It is typically prescribed after an individual has completed detoxification and is no longer consuming alcohol. It is important to note that acamprosate is not used to treat acute alcohol withdrawal symptoms, nor does it reduce the immediate effects of alcohol if consumed. Instead, its purpose is to help prevent relapse by reducing the cravings and discomfort associated with prolonged abstinence.

How Acamprosate Works

Chronic alcohol consumption can significantly disrupt the natural balance of neurotransmitters in the brain, particularly glutamate (an excitatory neurotransmitter) and gamma-aminobutyric acid (GABA, an inhibitory neurotransmitter). This imbalance can contribute to cravings and feelings of unease during abstinence. Acamprosate is believed to work by

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Acamprosate is approved for (FDA label)

Acamprosate calcium is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with acamprosate calcium should be part of a comprehensive management program that includes psychosocial support. The efficacy of acamprosate calcium in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium treatment. The efficacy of acamprosate calcium in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed. Acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation (1, 14).

Source: Read the full FDA label on DailyMed. Label effective date: July 14, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Acamprosate (FDA label)

Acamprosate calcium delayed-release tablets, 333 mg are white to off white, round shaped enteric-coated tablets debossed with AC on one side and ‘476’ on the other side and free from physical defects. Enteric-coated tablets, 333 mg (3).

Source: FDA prescribing information (DailyMed). Set ID: 1cfe4675-766f-4f1a-b1a8-96bbdacfcfa5. Label effective date: July 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Acamprosate (FDA label)

Common adverse events that occurred in any acamprosate calcium treatment group at a rate of 3% or greater and greater than the placebo group in controlled clinical trials with spontaneously reported adverse events are: accidental injury, asthenia, pain, anorexia, diarrhea, flatulence, nausea, anxiety, depression, dizziness, dry mouth, insomnia, paresthesia, pruritus and sweating (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Somerset Therapeutics, LLC at 1-800-417-9175, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 1cfe4675-766f-4f1a-b1a8-96bbdacfcfa5. Label effective date: July 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Acamprosate (FDA label)

Acamprosate calcium is contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components (4.1). Acamprosate calcium is contraindicated in patients with severe renal impairment (4.2). 4.1 Hypersensitivity to Acamprosate Calcium Acamprosate calcium is contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components. 4.2 Severe Renal Impairment Acamprosate calcium is contraindicated in patients with severe renal impairment (creatinine clearance of ≤30 mL/min) [ see Dosage and Administration ( 2.1 ), Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.6 ), and Clinical Pharmacology ( 12.3 ) ].

Source: FDA prescribing information (DailyMed). Set ID: 1cfe4675-766f-4f1a-b1a8-96bbdacfcfa5. Label effective date: July 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Acamprosate (FDA label)

Dose reduction is required for patients with moderate renal impairment (5.1).

Source: FDA prescribing information (DailyMed). Set ID: 1cfe4675-766f-4f1a-b1a8-96bbdacfcfa5. Label effective date: July 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Acamprosate (FDA label)

Acamprosate does not affect the pharmacokinetics of alcohol. The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ].

Source: FDA prescribing information (DailyMed). Set ID: 1cfe4675-766f-4f1a-b1a8-96bbdacfcfa5. Label effective date: July 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.